BLA 125349 · Human Genome Sciences Inc.
Raxibacumab
Raxibacumab · Iv (Infusion) · Anthrax Protective Antigen-directed Antibody
NovelPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Jun 2, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2012
Dec 14, 2012
Approved uses
n/a
Original approval plus efficacy supplements
Registered trials
4
2 Phase 3, 0 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
No approvals could be loaded from Drugs@FDA just now.
Clinical trials
Interventional ClinicalTrials.gov studies with "Raxibacumab" as an intervention, any sponsor and status, largest first.
- Effect of Raxibacumab on Immunogenicity of Anthrax Vaccine AdsorbedPivotal-lookingCompleted
Emergent BioSolutionsIndustry
NCT02339155 · 573 participants · Start Feb 24, 2015 · Primary completion Jan 3, 2017
Drug: AVA; Raxibacumab and 1 more · For: Infections, Bacterial
Sites: Edgewater, Florida; Overland Park, Kansas; Knoxville, Tennessee
- A Study to Evaluate the Safety and Tolerability of Raxibacumab in Healthy SubjectsPivotal-lookingCompleted
Human Genome Sciences Inc.Industry
NCT00639678 · 322 participants · Start Mar 2008 · Primary completion Jul 2008
Drug: placebo; raxibacumab and 2 more · For: Healthy
- Clinical Benefit and Safety of Raxibacumab in Patients With Symptomatic Inhalational Anthrax in a Mass Exposure ScenarioNot yet recruiting
Emergent BioSolutionsIndustry
NCT02177721 · 100 participants (planned) · Start Jan 2027 · Primary completion May 2035
Drug: Sample Collection · For: Infections, Bacterial
- An Open-label, Nonrandomized Study to Evaluate the Safety and Immunogenicity of Raxibacumab With ReinjectionPivotal-lookingCompleted
Human Genome Sciences Inc.Industry
NCT02016963 · 20 participants · Start Jan 31, 2008 · Primary completion May 31, 2008
Drug: Raxibacumab · For: Therapeutic Treatment of Inhalation Anthrax
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Population pharmacokinetics of raxibacumab in healthy adult subjects.
Oosterholt SP, Della Pasqua O · Br J Clin Pharmacol 2021 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Effect of raxibacumab on immunogenicity of Anthrax Vaccine Adsorbed: a phase 4, open-label, parallel-group, randomised non-inferiority study.
Skoura N, Wang-Jairaj J, Della Pasqua O, et al. · Lancet Infect Dis 2020 · Clinical Trial, Phase IV, Randomized Controlled Trial
- Raxibacumab for the treatment of inhalational anthrax.
Migone TS, Subramanian GM, Zhong J, et al. · N Engl J Med 2009 · Multicenter Study, Randomized Controlled Trial
- A systematic review and meta-analysis of preclinical trials testing anti-toxin therapies for B. anthracis infection: A need for more robust study designs and results.
Xu W, Ohanjanian L, Sun J, et al. · PLoS One 2017 · Meta-Analysis, Systematic Review
Sponsor: Human Genome Sciences Inc.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.